A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 51, Issue 5, 2011, Pages 452-454

  Whitehead, Julie ^a,b   Toledo, Manuela G ^a,b   Stern, Catharyn J ^a,b  

^a MELBOURNE IVF   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

chemotherapy; gonadotrophin releasing hormone (GnRH); ovarian function

Indexed keywords

CETRORELIX; CYCLOPHOSPHAMIDE; FOLLITROPIN; INHIBIN A; INHIBIN B; PROGESTERONE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FOLLITROPIN BLOOD LEVEL; HOT FLUSH; HUMAN; LYMPHOMA; MENSTRUATION; MULTIPLE CYCLE TREATMENT; OVARY FUNCTION; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SARCOMA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; FERTILITY PRESERVATION; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INHIBINS; LYMPHOMA; ORGANS AT RISK; OVARY; PILOT PROJECTS; PRIMARY OVARIAN INSUFFICIENCY; YOUNG ADULT;

EID: 80054013011     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2011.01346.x     Document Type: Article

References (13)

1. Meirow D, Nugent D,. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7: 535-543. (Pubitemid 33069611)
2. Meirow D, Assad G, Dor J,. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004; 19 (6): 1294-1299. (Pubitemid 38807699)
3. Gougeon RG,. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996; 17: 121-155.
4. Oktay K, Briggs D, Gosden RG,. Onteny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 1997; 82: 3748-3751. (Pubitemid 27509366)
5. McNatty KP, Heath DA, Lundy T, et al. Control of early follicular development. J Reprod Fertil Suppl 1999; 5: 1-16.
6. Kiesel LA, Rody AR, Greb RR, Szilagyi A,. Clinical use of GnRH analogues. Clin Endocrinol 2002; 56 (6): 677-687. (Pubitemid 34785898)
7. Ortmann O, Diedrich K,. Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues. Hum Reprod 1999; 14 (1): 94-206.
8. Meduri G, Touraine P, Beau I,. Delayed puberty and primary amenorrhoea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J Clin Endocrinol Metab 2003; 88: 3491-3498. (Pubitemid 37034482)
9. Meirow D, Epstein M, Lewis H, et al. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001; 16 (4): 632-637. (Pubitemid 32293787)
10. Mardesic T, Snajderova M, Sramkova L, et al. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004; 25 (1): 90-92. (Pubitemid 38165928)
11. Fogelman I,. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 1992; 57 (4): 715-724.
12. Blumenfeld Z, Avivi I, Ritter M, Rowe JM,. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 1999; 6 (5): 229-239. (Pubitemid 29494928)
13. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11 (8): 1620-1626. (Pubitemid 26318897)